Opinion|Videos|April 4, 2025
Real-World Implications of Changes in CDR-SB Score in Patients Receiving Amyloid-Targeting Therapy
Panelists discuss how clinicians should interpret Clinical Dementia Rating-Sum of Boxes (CDR-SB) score changes by correlating numerical shifts with meaningful real-world outcomes, considering both the statistical significance and clinical meaningfulness of changes, recognizing that even modest improvements may represent significant functional preservation for patients, and contextualizing these changes within individual patient circumstances, disease trajectory, and impact on quality of life.
Advertisement
Video content above is prompted by the following:
- How should clinicians interpret changes in CDR-SB scores in terms of real-world functional and cognitive benefits for patients?
Advertisement
Related to this article
Karen van Caulil, PhD, on how employers can improve cancer care by investing in access, prevention, and support through treatment and survivorship.
Each additional hour of nightly CPAP use was associated with 13% lower all-cause mortality risk in a French cohort of adults with sleep apnea.
AI-assisted spirometry, imaging biomarkers, and population screening strategies highlighted early detection and prevention as a throughline at the ERS Congress.
Ultimately, causality could not be established due to lack of data on disease severity and socioeconomic status, among others.
A systematic review finds people with narcolepsy and idiopathic hypersomnia often stay employed but face work impairment and limited workplace support.
Laura Fabbri, MD, discusses bridging idiopathic pulmonary fibrosis (IPF) and oncology research and putting patients at the center of trial design.
Finerenone is the first new FDA-approved treatment in more than 30 years for adults with CKD associated with type 1 diabetes.
Karolinska Institutet reports ROR1 inhibitor KAN571C wipes out double‑resistant MCL after ibrutinib/venetoclax, spotlighting a promising target.
Advertisement
Advertisement
Trending on AJMC
1
FDA Expands Finerenone Approval to CKD Associated With Type 1 Diabetes
2
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
3
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
4
Twice-Yearly CD19 Therapy Targets MG Root Cause: Richard Nowak, MD, MS
5